1,721,065 research outputs found
Letter by Calabrò et al Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)"
No full textReply to ‘Oral formulation and SGLT2i interaction: key nuances in semaglutide’s effect on atrial fibrillation’
No full textLipid-lowering therapy in high cardiovascular risk patients during COVID-19 pandemic: keep focused on the target
Full text linkTo the Editor COVID-19 (COrona VIrus Disease) patients with cardiovascular (CV) disease, multiple CV risk factors or comorbidities (i.e., arterial hypertension and diabetes) were shown to be more prone to a worse prognosis. SARS-CoV-2 is a still unknown enemy and the role of concomitant cardiovascular therapies has been controversial in the early stages, particularly with regard to Angiotensin-Converting Enzyme inhibitors..
Geographic variations in percutaneous versus surgical coronary revascularization: A global perspective from the SYNTAXES trial
No full textGeographic variations in percutaneous versus surgical coronary revascularization: A global perspective from the SYNTAXES tria
Ticagrelor monotherapy after acute coronary syndrome: lessons from the ULTIMATE-DAPT trial
No full textMultimodality evaluation of cardiac injury in COVID-19: Getting to the heart of the matter
No full textMultimodality evaluation of cardiac injury in COVID-19: Getting to the heart of the matte
- …
